AU2013303302B2 - Nt-proCNP as a biomarker of vascular disorders and pregnancy complication - Google Patents

Nt-proCNP as a biomarker of vascular disorders and pregnancy complication Download PDF

Info

Publication number
AU2013303302B2
AU2013303302B2 AU2013303302A AU2013303302A AU2013303302B2 AU 2013303302 B2 AU2013303302 B2 AU 2013303302B2 AU 2013303302 A AU2013303302 A AU 2013303302A AU 2013303302 A AU2013303302 A AU 2013303302A AU 2013303302 B2 AU2013303302 B2 AU 2013303302B2
Authority
AU
Australia
Prior art keywords
ntprocnp
pregnancy
subject
level
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013303302A
Other languages
English (en)
Other versions
AU2013303302A1 (en
Inventor
Eric Arnold Espiner
Timothy Charles Ramsey Prickett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otago Innovation Ltd
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of AU2013303302A1 publication Critical patent/AU2013303302A1/en
Application granted granted Critical
Publication of AU2013303302B2 publication Critical patent/AU2013303302B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013303302A 2012-08-13 2013-08-13 Nt-proCNP as a biomarker of vascular disorders and pregnancy complication Ceased AU2013303302B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682729P 2012-08-13 2012-08-13
US61/682,729 2012-08-13
PCT/NZ2013/000142 WO2014027899A1 (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Publications (2)

Publication Number Publication Date
AU2013303302A1 AU2013303302A1 (en) 2015-03-12
AU2013303302B2 true AU2013303302B2 (en) 2017-10-12

Family

ID=50101335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013303302A Ceased AU2013303302B2 (en) 2012-08-13 2013-08-13 Nt-proCNP as a biomarker of vascular disorders and pregnancy complication

Country Status (9)

Country Link
US (1) US10012656B2 (https=)
EP (1) EP2883060B1 (https=)
JP (1) JP6423788B2 (https=)
CN (1) CN104937420B (https=)
AU (1) AU2013303302B2 (https=)
CA (1) CA2882116A1 (https=)
IN (1) IN2015KN00571A (https=)
SG (2) SG11201501145SA (https=)
WO (1) WO2014027899A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
JP6423788B2 (ja) * 2012-08-13 2018-11-14 オタゴ イノベーション リミテッド 血管障害及び妊娠合併症のバイオマーカーとしてのＮＴ−ｐｒｏＣＮＰ
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016064815A1 (en) * 2014-10-20 2016-04-28 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
TWI776812B (zh) * 2016-06-02 2022-09-11 荷蘭商菲林公司 血管收縮素-1-受體拮抗劑
WO2018216580A1 (ja) * 2017-05-22 2018-11-29 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
WO2019199869A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in physiological samples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014885A2 (de) * 1999-08-20 2001-03-01 Biomedica Gesellschaft Mbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099139A1 (en) 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
DK1644740T3 (da) * 2003-06-17 2011-02-21 Otago Innovation Ltd Vurdering af skeletal vækst ved anvendelse af målinger af NT-CNP-peptider
DE10338733A1 (de) 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
US20100041989A1 (en) 2006-09-29 2010-02-18 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
CN103109192A (zh) * 2010-06-18 2013-05-15 塞尚公司 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物
US20150293119A1 (en) 2011-12-23 2015-10-15 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
JP6423788B2 (ja) * 2012-08-13 2018-11-14 オタゴ イノベーション リミテッド 血管障害及び妊娠合併症のバイオマーカーとしてのＮＴ−ｐｒｏＣＮＰ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014885A2 (de) * 1999-08-20 2001-03-01 Biomedica Gesellschaft Mbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HENNESSY, A., "Precursors to pre-eclampsia: are there markers in the fetal circulation?", CLINICAL SCIENCE, (2004), vol. 106, pages 449 - 450 *
PRICKETT, T.C.R. ET AL., "N-terminal pro-C-type natriuretic peptide, but not C-type natriuretic peptide, is greatly elevated in the fetal circulation", CLINICAL SCIENCE, (2004), vol. 106, pages 535 - 540 *
VLACHOPOULOS, C. ET AL., "Amino-terminal pro-C-type natriuretic peptide is associated with arterial stiffness, endothelial function and early atherosclerosis", ATHEROSCLEROSIS, (2010), vol. 211, pages 649 - 655 *
WRIGHT, S.P. ET AL., "Amino-terminal pro-C-type natriuretic peptide in heart failure", HYPERTENSION, (2004), vol. 43, pages 94 - 100 *
ZAKERI, R. ET AL., Circulation, 2011, vol. 124, no. 21, Suppl.S, A10128 (Abstract 10128) *

Also Published As

Publication number Publication date
IN2015KN00571A (https=) 2015-07-17
JP2015526725A (ja) 2015-09-10
US10012656B2 (en) 2018-07-03
EP2883060B1 (en) 2018-03-21
US20150241451A1 (en) 2015-08-27
CN104937420B (zh) 2018-07-03
CA2882116A1 (en) 2014-02-20
WO2014027899A1 (en) 2014-02-20
EP2883060A4 (en) 2016-06-29
EP2883060A1 (en) 2015-06-17
SG11201501145SA (en) 2015-04-29
CN104937420A (zh) 2015-09-23
SG10201700872TA (en) 2017-04-27
JP6423788B2 (ja) 2018-11-14
AU2013303302A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
AU2013303302B2 (en) Nt-proCNP as a biomarker of vascular disorders and pregnancy complication
EP2281203B1 (en) A marker for graft failure and mortality
JP5684904B2 (ja) 妊娠高血圧症及び子癇前症の予後診断とリスクの評価のためのマーカー
EP2834638B1 (en) Methods for diagnosis and prognosis of sepsis
JP6639392B2 (ja) 胎盤成長因子２の選択的測定法
EP2368119B1 (en) Method for determining the risk of preeclampsia using pigf-2 and pigf-3 markers
CA2859295A1 (en) Biomarkers and parameters for preeclampsia
EP2601522B1 (en) Method for diagnosing pre-eclampsia
US20250327817A1 (en) Detection of predictors of preeclampsia
US20140127703A1 (en) Method for Diagnosing Preeclampsia
JP2022544942A (ja) 小児患者における腎機能を診断若しくはモニタリングする、又は腎機能障害を診断する方法
EP2385372A1 (en) Kidney disease in normal and abnormal pregnancy
KR101075100B1 (ko) 자간전증 진단에 유용한 정보를 제공하기 위한 방법 및 키트
HK1228503A1 (en) Method for the selective determination of placental growth factor 2
HK1228503B (zh) 用於选择性确定胎盘生长因子2的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired